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New Recommendations on International
Human Research: Can Minimum Standards
Prevent the Exploitation of Vulnerable
Human Subjects in Developing Countries?
Rebecca A. Finkenbinder*
I.

Abstract

Developed countries conduct clinical trials on humans in developing
countries, primarily as the result of seeking lower costs. Specifically, the
United States conducted HIV trials in Africa to test a new treatment to
prevent the spread of AIDS from a mother to her child during birth.
While the treatment is certainly worthwhile, the research utilized
compromising ethical standards instead of the requisite United States
human research regulations. In April 2001, new regulations were
proposed by the National Bioethics Advisory Committee (NBAC) to
govern such inconsistencies. Unfortunately, these recommendations,
conceded by the NBAC to be "minimum standards," are not sufficient to
prevent the continuous exploitation of vulnerable research participants.
II.

The Call for Regulation

In recent years, the scope of human research has rapidly expanded
into the international playing field. Market forces, such as a steady
decrease in federal funds, have spurred pharmaceutical, biotechnology
and medical device companies to be more efficient in their methodology
of conducting research.'
The United States and other developed
countries have started to look outside their boundaries toward new
sources for research subjects - developing countries. Poverty stricken
* J.D. Candidate, The Dickinson School of Law of The Pennsylvania State
University, 2003.
1.
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TRIALS IN DEVELOPING COUNTRIES: EXECUTIVE SUMMARY, at i (2001) (hereinafter
EXECUTIVE

SUMMARY)

/nbac/pubs.html.

available

at

http://www.georgetown.edu/research/nrcbl

PENN STATE INTERNATIONAL LAW REVIEW

[Vol. 21:2

and unable to receive even minimal healthcare, individuals in developing
countries are vulnerable and serve as easy targets for scientists seeking
subjects of research studies.2
Research studies conducted in these developing countries are highly
scrutinized, considering the widespread potential for exploitation and
unethical behavior. There are currently numerous sources of guidelines
to help regulate the ethical conduct of researchers. None have thus far
served as the necessary binding authority to ensure the protection of
human subjects. A recent administrative study resulted in the proposal of
"minimum standards" intended to promote human rights and increase the
welfare of every research participant. The question remains whether
these elementary guidelines will protect and stop the exploitation of
vulnerable human beings.
This comment examines the new "minimum standards" as they are
applied to studies conducted in developing countries, with particular
attention to a recent research study conducted in Africa. In Section III, a
detailed description of the drug trials is given in addition to an analysis
of the resulting ethical controversy. Section IV provides a review of the
most relevant national and international human research guidelines.
Section V discusses the new recommendations recently proposed to
address unethical behavior that has now become prevalent when
developed countries conduct research in developing countries.
Moreover, this section will analyze whether the new standards would
have protected the human subjects in the African drug trials. Finally,
Section VI provides a brief summary of the comment.
III. The AIDS Epidemic
Since its dawning, the human immunodeficiency virus (HIV)
pandemic has adversely affected approximately five million children,
ninety percent of whom live in Africa. 4 Of those with the disease, more
than one million children contracted HIV through mother-to-child
transmission (MTCT).5 MTCT of HIV can occur during pregnancy,
2. M. Dickens, Research Ethics and HIV/AIDS, 16 MED. & L. 187, 196 (1997).
3. EXECUTIVE SUMMARY, supra note 1, at xiv.
4. Mother-to-Child Transmission of HIV (3): Technical Update, available at
http://www.unaids.org/publications/documents /mtct/index.html (last visited Oct. 16,
2002) [hereinafter Mother-to-Child Transmission]. Current estimates suggest that
600,000 children are infected annually, the majority living in sub-Saharan Africa. Nine
out of ten children who are infected live in this region. A Review of HIV Transmission
through Breastfeeding(December 1998) at Id. [hereinafter Breastfeeding Transmission].
5. Developing Options for PerinatalHIV Prevention in the Developing World
Researchers Worldwide Collaborate to Develop Practical Therapies (June 1997), at
http://www.aidsinfo.nih.gov/, Article A00350 (last visited Dec. 29, 2002) [hereinafter
PerinatalHIV Prevention].

2003]

INTERNATIONAL HUMAN RESEARCH

delivery, or breastfeeding. 6 Women in sub-Saharan Africa have the
highest rates of MTCT, due to the fact that many women breastfeed for
approximately two years.7
Despite the apparent link between
breastfeeding and the transmission of HIV, infants born to HIV-infected
mothers continue to acquire this fatal disease because breastfeeding is
8
more economical in developing countries.
A.

AZT Trials in United States

An overwhelming source of HIV infection in children, MTCT has
caught the attention of the United States federal government, sparking a
plethora of federally funded research studies worldwide. In 1991, the
National Institute of Health (NIH) conducted an HIV clinical trial, in the
United States, entitled ACTG-076 (hereinafter "the 076 regime.") The
women in the study agreed to receive a drug, AZT, or a placebo
throughout their pregnancies and delivery. Neither the subjects nor the
9
doctors knew which "treatment" was given.
In early 1994, results of the trial concluded that it is possible to
reduce the risk of MTCT of HIV by as much as two-thirds by giving
HIV-infected women AZT during pregnancy, labor, and delivery, and
subsequently administering AZT to the newborn infants. 10 As a result,
the study came to a halt in fifty-nine medical centers; officials ordered
AZT be administered in place of the placebo to the women participating
in the study. 1" Subsequently, the 076 regime became the "standard of
care" in the United States.' 2 As a result of this new drug, HIV infections
in children living in the United States dramatically decreased. 13
6. Breastfeeding Transmission,supra note 4.
7. Id.
8. New Data on the Prevention of Mother-to-Child Transmission of HIV and their
Policy Implications: Conclusions and Recommendations (Jan. 15, 2001), at
http://www.unaids.org/publications/documents /mtct/index.html (last visited Oct. 16,
2002). Twenty-five to 35% of HIV-positive women's babies will become infected in
developing countries, while the probability of transmission in industrialized countries is
only 15% to 25%. Mother-to-ChildTransmission,supra note 4.
9. Lawrence K. Altman, In Major Finding, Drug Curbs HI. V. Infection in

Newborns, N.Y. TIMES, Feb. 21, 1994, at Al.
10. Perinatal HIV Prevention, supra note 5. See also CDC Studies of AZT to
Prevent Mother-to-Child HIV Transmission in Developing Countries: Questions and

Answers (June 1997), at http://www.hivatis.org/devlques.html (last visited Oct. 16, 2002)
[hereinafter Questions andAnswers].
11. Altman, supranote 9.
12. Questions andAnswers, supra note 10.
13. Id. Three years after the trials, the number United States children born with HIV
had decreased to approximately 500 per year, as compared with 1,800 per year in the
early 1990s. Susan Okie, HIV Transmission's Two Worlds; Mother-to-Baby Rates Down
Here, Not in Poor Countries, THE WASH. POST, Sep. 16, 1997, at Z07 [hereinafter Baby
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Implementing AZT Throughout the World

B.

A conference was held shortly after the trial in the United States
was complete; researchers and health practitioners worldwide convened
to discuss the implications of the results for developing countries.1 4 The
panel suggested the 076 regime be used in industrialized nations, but
agreed that it would need to be altered before implemented in developing
countries.15 In its recommendations, the international panel focused its
research efforts on a simpler, less costly drug regime, due to many
the implementation of the 076 regime in the newly
obstacles precluding
16
world.
developed
1.

Barriers to Implementation

Among the barriers that influenced the panel's decision to preclude
the implementation of the 076 regime in underdeveloped countries such
as Africa were the cost and feasibility of the drug treatment. Drug costs
alone for the 076 regime were estimated around $800,17 which was
eighty times the annual budget per person in many developing nations. 18
The panel also deemed the 076 regime unfeasible due to its requirements
that women be treated early in their pregnancy and receive intravenous
administration of AZT.' 9 In developing nations, women infrequently
seek and receive prenatal care, 20 and intravenous treatment is not readily
available. 2'
Due to these obstacles to implementation and the fact that no
treatment is available in most developing countries, the panel
recommended that placebo-controlled trials be designed to provide
faster, yet valid assessments of drug treatments to HIV-infected
women. 22 Despite the fact that there is a standard of care in the United
Rates]. The 076 regime is estimated to save the life of one of every seven children born
to HIV-infected women. Peter Lurie & Sidney M. Wolfe, Unethical Trials of
Interventions to Reduce PerinatalTransmission of the Human Immunodeficiency Virus in
Developing Countries, 337 N. ENGL. J. MED. 853, 853 (1997).
14. PerinatalHIV Prevention, supra note 5.

15.

Id.

16. Id.
17. Costs to treat both the pregnant mother and the newborn range between $400 to
$900. Baby Rates, supra note 13.
18. PerinatalHIV Prevention, supra note 5. Annual national health budgets in the
developing world are generally less than $10 per person. Questions and Answers, supra
note 10.
19. PerinatalHIV Prevention, supra note 5.
20. Most pregnant women in developing countries do not seek prenatal care until
they begin labor. Mother-to-ChildTransmission, supra note 4.
21. PerinatalHIV Prevention, supranote 5.

22. Id.
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States, a placebo-controlled design was developed, with the rationale that
alternative regimes should be compared to the standard of care in most
23
developing countries, that is, no treatment.
2.

Modified AZT Trials in Africa

As a result of these recommendations, the NIH and the Centers for
Disease Control and Prevention (CDC) financed placebo-controlled
studies conducted in developing countries, with an emphasis in Africa.24
In particular, studies in the Cote d'Ivoire (hereinafter "Ivory Coast")
were conducted that consisted of a shorter course AZT regimen given to
HIV-infected women late in their pregnancies. 25 Specifically, the women
only received oral AZT in the last four weeks of pregnancy and during
labor, as compared to the trial in the United States where the women
received AZT orally for sixteen to twenty-four weeks and intravenously
during childbirth.2 6 Researchers, in an attempt to find an affordable and
feasible therapy option in the developing world, believed this newly
designed regimen would prove to be effective, safer and could be
realistically implemented.27
Critics argue that the shorter dose regimen research is unethical as
administered in developing countries because the research makes use of a
placebo in the study, while there is already a clinically proven treatment
that is now the standard of care in the United States. The CDC, in fact,
has conceded that scientific studies are usually conducted by comparing
a new treatment with the standard treatment. 28 As a result, opponents of
the studies declare all perinatal transmission studies that use placebos
unethical; any regimen shorter and more economical should be compared
to the longer course of AZT.2 9
In particular, critics argue that
approximately 1,000 babies of women in these studies could have been
spared becoming infected with HIV through MTCT if their mothers had
been assigned the standard treatment and not a placebo.3 °
Defenders of the placebo-controlled studies argue that the standard
of care in the host country is to be considered the standard, which, in this

23. Id.
24. See Questions andAnswers, supra note 10.
25. Id.
26. Id. In addition, while the United States' trial gave the newborns AZT for six
weeks after their births, the much shorter regimen in the Ivory Coast gave no infant dose
because it was simpler and less expensive. PerinatalHIV Prevention, supra note 5.
27. PerinatalHIV Prevention,supra note 5.
28. See Questions and Answers, supra note 10.
29. David Brown, AZT's Success in PregnancyMay Help Expand AIDS Treatment
for Poor,THE WASH. POST, Feb. 19, 1998, at A10.
30. Baby Rates, supra note 13.
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case, is no treatment at all.31 , These health officials agree to the
administration of a smaller dose because it would be a faster and more
economical method of treatment in developing countries that would not
normally be available to those HIV-infected women.3 2 The CDC is
adamant that a study comparing a shorter dose to the clinically proven
longer dose "would not indicate whether the short AZT regimen was
better than the currently available intervention[] (nothing at all)."33
At the same time that the shorter regimen was administered to Ivory
Coast women, similar trials were conducted in Thailand.34 On February
18, 1998, a nearly completed study in Thailand revealed that a short and
relatively inexpensive regimen of AZT is almost as effective as the
longer dose administered in 1994 to the women in the United States.35
Consequently, health officials recommended all other studies, including
those in the Ivory Coast, to stop the use of placebos. 36 Critics of the
placebo-controlled studies believe that the decision to cease the use of
placebos is dispositive that the practice is unethical.3 7
Unfortunately, the effectiveness of AZT in substantially decreasing
the transmission of HIV to newborns has only been realized in nonIn populations like the Ivory Coast, where
breastfed infants. 38
breastfeeding is not only the norm but also the only economical method
of feeding, these studies are severely limited in their effectiveness and
application in developing countries.3 9
If the shorter dose of AZT is not as effective in breastfeeding
women, 40 why do they remain the targets of federal funding for drug
31. Brown, supra note 29. "The standard of care for treating HIV-infected
pregnancies in most developing countries remains 'no intervention."' Questions and
Answers, supra note 10.
32. Baby Rates, supra note 13. "The tests are better than nothing and [the] country
cannot afford the luxury of rejecting studies not in conformance with standards required
in America." Jay Dyckman, The Myth of Informed Consent: An Analysis of the Doctrine
of Informed Consent and its (Mis)Application in HIV Experiments on Pregnant Women in
Developing Countries, 9 COLUM. J. GENDER & L. 91, 107 (1999).
33. See Questions andAnswers, supra note 10.
34. In addition to the Ivory Coast, AZT studies were conducted in Thailand, Uganda
and Ethiopia. Baby Rates, supra note 13.
35. Brown, supra note 29. The Thailand data revealed that an abbreviated regimen,
costing 10% of the standard of care in the United States ($80 rather than $800), decreased
MTCT by half. Mervyn Susser, The Prevention of PerinatalHIV Transmission in the
Less-Developed World, 88 AM. J. PUB. HEALTH 547 (1998).
36. Id.
37. Sheryl Stolberg, Use of Placebo is Endedfor H.l V. Study in Africa, N.Y. Times,
Oct. 24, 1997, at Al.
38. Breastfeeding Transmission,supra note 4.
39. Many obstacles to replacement feedings that HIV-infected mothers in
developing countries face include stigma, affordability, risk to the infant of other
infections and malnutrition. Id.
40. "Results from a number of studies in breastfeeding populations indicate that a
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research? Perhaps industrialized nations are exploiting those in other
countries by taking advantage of and capitalizing on their unfortunate
situations; in this case, the AIDS epidemic.
C.

ControversyErupts RegardingEthicalIssues

The consensus remained that the full 076 regimen could not be
implemented as the standard of care in developing nations. 41 Both sides
of the controversy agreed that perinatal HIV transmission is a grave
problem meriting concerted international attentions; that the ACTG 076
trial was a major breakthrough in perinatal HIV prevention; that there is
a role for research on this topic in developing countries; that identifying
less expensive, similarly effective interventions would be of enormous
benefit, given the limited resources for medical care in most developing
countries; and that randomized studies can help identify such
interventions.4 2
One point of disagreement in this ethical controversy, however, is
what comparison group should be used when there is a known effective
43
intervention, but a more economical intervention is being tested?
Another important ethical consideration is whether there are known
mechanisms for implementing the shorter dose once the studies are
complete. Women in developing countries cannot afford even the
shorter dose; therefore, the less effective, low-cost interventions improve
upon nothing at all. 4
International AIDS officials rely on donations and price breaks by
the manufacturer of AZT,45 so that the two to three million women a year
who need treatment can have access to the drug.46 However, the NIH,
the CDC and the host countries have not developed a plan as to how to

short course of [AZT] can still reduce the transmission of HIV from the mother to the
baby, though not as well as when mothers do not breastfeed." Mother-to-Child
Transmission,supra note 4.
41. Questions and Answers, supra note 10. The consensus is among the World
Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS),
and those countries where the trials are being conducted. Id.
42. Lurie & Wolfe, supra note 13, at 854.
43. See id.
44. Susser, supra note 35. "The particular and pressing issue is how to make the
new intervention, or other alternatives to the standard regimen, affordable in the poorest
nations." Id. One critic of the placebo-controlled studies goes as far to say that the
research conducted was "inexcusable" and "sloppy" because "they have wasted a large
number of lives and a huge amount of money" doing it. Sheryl Gay Stolberg, Placebo
Use is Suspended in Overseas AIDS Trials, N.Y. TIMEs, Feb. 19, 1998, at A6.
45. Glaxo-Wellcome is the manufacturer of AZT.
46. See Brown, supra note 29.
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make the interventions available, 47 and have given no realistic assurances
that a plan will emerge. Therefore, the mere assertions by health
advocates that the interventions are feasible in developing nations is
simply "just paying lip service" and is not "good enough '4 8 to help needy
women and children. In fact, a South Africa pediatrician wonders if the
health officials who financed the trials will pay for the women in her
and claims "they
country to receive the drug after the study is completed
49
is."
mouth
their
where
money
their
put
should
The NIH and the CDC maintain that the Ivory Coast research is
ethical, primarily because there is no current treatment available. 50 In
addition, the CDC believes that the studies are consistent with both the
United States and international human research ethical standards.51
Furthermore, the CDC feels compelled to conduct such studies, as it may
be unethical not to undertake them, considering its ability to address such
a critical international issue.52
Another argument in favor of the trials is that the host countries, in
fact, approached the United States to help find a treatment that is better
than what they have now. 53 Yet government records show that African
collaborators of the studies did not feel comfortable using a placebo and
a Harvard doctor in the Thailand trials refused to administer any dummy
medications.5 4 In fact, none of the Thai women in the Thai government's
study received a placebo. 55 Nevertheless, the trials conducted in the
Ivory Coast continued to use a placebo when a known dosage of AZT
was determined effective and could eliminate the deaths of many
children.56

47. George J. Annas & Michael A. Grodin, Human Rights and Maternal-FetalHIV
Transmission Prevention Trials in Africa, 88 AM. J. PuB. HEALTH 560 (1998) [hereinafter
Maternal-FetalHIV Transmission].
48. Id.
49. Sheryl Gay Stolberg, U.S. AIDS Research Abroad Sets Off Outcry Over Ethics,
N.Y. TIMEs, Sep. 18, 1997, at Al [hereinafter Ethics Outcry].
50. Questions and Answers, supra note 10. In fact, the CDC stated "'the idea that
there is AZT somewhere in the world doesn't have a real bearing on the lives of these
children and their mothers."' Susan Okie, Researchers Assailed for AIDS Studies on
Pregnant Women in Third World, THE WASH. POST, Sep. 18, 1997, at A13 [hereinafter
AIDS Studies].
51. See Questions and Answers, supra note 10.
52. See id.
53. AIDS Studies, supra note 50. See also David D. Ho, It's AIDS, Not Tuskegee;
Inflammatory Comparisons Won't Save Lives in Africa, TIME, Sep. 29, 1997, at 83.
("African researchers sought sponsorship from U.S. health agencies.")
54. Ethics Outcry, supra note 49.
55. Id.
56. See infra text accompanying note 152.
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IV. Human Research Regulations
The AZT trials were certainly not the first research studies
conducted on human beings. Human research is commonplace in the
medical industry and the need for regulation in this growing area arose
long before HIV and AIDS. Unfortunately, the conduct that spurred the
first guidelines is analogous to the AZT trials - both resulted in the
death of many innocent lives.
A.

InternationalRegulations

1.
The Nuremberg Code
The atrocities committed by the Nazis during the Second World
War resulted in the creation of an ethical framework that has served as a
guide for all current and future regulation of human experimentation. An
inhuman combination of Social Darwinism, Nazi ideology and "racial
hygiene" fostered an atmosphere where innocent victims were exploited
and subject to hideous crimes. 7 Following the war, twenty-three Nazi
physicians and scientists were charged with war crimes involving the
performance of medical experiments on nonconsenting prisoners held
58
primarily at concentration camps.
The Doctors' Trial 59 (the "Trial") was held in postwar Nuremberg
Germany in December 1946 and concluded eight months later. 60 The
Trial provided the opportunity to analyze the legal and ethical
implications of human experimentation. As a result, The Nuremberg
Code (the "Code"), was drafted by four American judges, 6 1 not as a code
57. GEORGE J. ANNAS & MICHAEL A. GRODIN, Introduction, in THE NAZI DOCTORS
AND THE NUREMBERG CODE: HUMAN RIGHTS IN HuMAN EXPERIMENTATION at 3, 7

(George J. Annas & Michael A. Grodin eds., 1992) [hereinafter THE NAZI DOCTORS].
58. The court's judgment described the hideousness of the crimes: "[A]ll of these
experiments involving brutalities, tortures, disabling injury, and death were performed in
complete disregard of international conventions, the laws and customs of war, the general
principles of criminal law as derived from the criminal laws of all civilized nations, and
Control Council, Law No. 10. Manifestly human experiments under such conditions are
contrary to 'the principles of the law of nations as they result from the usages established
among civilized people, from the laws of humanity, and from the dictates of public
conscience."' Judgment andAftermath, in THE NAZI DOCTORS, supra note 57, at 94, 104
[hereinafter Judgment].
59. Also known as the "Medical Case," ANNAS & GRODIN, Introduction, in THE
NAZI DOCTORS, supra note 57, at 4, and "The Case against the Nazi Physicians,"
ALEXANDER MITSCHERLICH & FRED MIELKE, Epilogue: Seven Were Hanged,in THE NAZI

DOCTORS, supra note 57, at 105 [hereinafter Epilogue].

60. Fifteen of the twenty-three were convicted, seven were hung to death, five
received life imprisonment, and four were sentenced to ten to twenty years imprisonment.
Seven were found not guilty. Epilogue, supra note 59, at 105.
61. President Truman appointed the four judges of the United States Military
Tribunal No. 1. See id. at 113. In addition, the Doctors' Trial was conducted under the
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of medical ethics, but formulated as part of the final legal judgment in
the criminal case.62 The court agreed that "certain basic principles
must
63
be observed in order to satisfy moral, ethical and legal concepts."
Consisting of ten principles,64 the Code serves as the hallmark for
all future regulations on the ethics of human experimentation 65 with the
underlying premise of protecting a research subject's rights and wellbeing.6 6 Though the Code identified its esseitial principle, voluntary
consent of a human subject, over fifty years ago, it has no doubt
influenced the world and its subsequent promulgation of ethical codes.
Notably, the informed voluntary consent principle was listed first.
Voluntary informed consent is its crucial centerpiece and, subsequently,
the protection
of subjects remains a paramount concern in any human
67
experiment.
Unfortunately, the Code is not a perfect document 68 and violations
surfaced shortly after its formulation. 69 Hence, the need for a more
comprehensive set of ethical regulations, promulgated by physicians, and
not judges, emerged. 70 The Code, however, would serve as a guide to a
new set of principles.

authority of the United States military, following United States' court procedures and
prosecuted by United States attorneys. See GEORGE J. ANNAS, The Nuremberg Code in
U.S. Courts: Ethics versus Expediency, in THE NAZI DOCTORS, supra note 57, at 201
[hereinafter Ethics versus Expediency].
62. See LEONARD H. GLANTZ, The Influence of the Nuremberg Code on U.S. Statutes
andRegulations, in THE NAZI DOCTORS, supra note 57, at 183.
63. Judgment, supranote 58, at 102.
64. See generally, The Nuremberg Code, reprinted in THE NAZI DOCTORS, supra
note 57, at 2.
65. MICHAEL A. GRODIN, Historical Origins of the Nuremberg Code, in THE NAZI
DOCTORS, supra note 57, at 121, 122 [hereinafter HistoricalOrigins].
66. SHARON PERLEY ET AL., The Nuremberg Code: An International Overview, in
THE NAZI DOCTORS, supra note 57, at 149, 165 [hereinafter InternationalOverview].
67. See HistoricalOrigins,supra note 65, at 122.
68. See InternationalOverview, supra note 66, at 168. The Code's "imperfections
do not, and should not, minimize its importance. For although the field of international
research ethics has evolved greatly over the past 40 years, its origins can always be traced
back to the 10 principles first enumerated at the trial of the Nazi physicians." Id.
69. See id at 157. One example of the United States violating the Code is its
conduct during the Vietnam War. United States soldiers breathed Agent Orange and
were subsequently harmed by this new chemical. ROBERT F. DRINAN, The Nuremberg
Principles in InternationalLaw, in THE NAZI DOCTORS, supra note 57, at 174, 179. See
also Ethics versus Expediency, supra note 61, at 219. ('The promise of the Nuremberg
Code has not been fulfilled in the United States.") In fact, the Code has never been used
in an United States court to award damages in a criminal case since its formation. While
the Code may serve as authority on criminal and civil standards of conduct, only one
Supreme Court case, United States v. Stanley, 483 U.S. 669, (1987), mentions it-in the
dissent. Ethics versus Expediency, at 201, 212.
70. InternationalOverview, supra note 66, at 157.
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2.
Declaration of Helsinki
The World Medical Association (WMA) began studying the
dilemma of the formation of a new ethical code 7' and, in 1964,
promulgated the Declaration of Helsinki (Helsinki 1).72 Helsinki I
identified five basic principles to be followed when humans serve as
subjects to experimentation.73 A notable difference between Helsinki I
and the Code is the location of the informed consent requirement.
Unlike the Code, Helsinki I does not include as one of its five basic
principles the critical principle of voluntary, informed consent.
While other differences are apparent, another significant difference
between the Code and Helsinki I is its clear differentiation between
"clinical research combined with professional care" and "nontherapeutic
clinical research. 74 It is within this distinction that Helsinki I placed the
profound informed consent principle and expanded the original consent
requirement to include a provision for those that are incapable of giving
consent and suggested that consent be obtained in writing.
Helsinki I was revised in 1975 (Helsinki II), 1983 (Helsinki III) and
1989 (Helsinki IV); Helsinki II is recognized as the fundamental
75
comprehensive set of principles for research involving human subjects.
Its final revision features twelve basic principles
and has been adopted
76
by international texts and national legislation.
Helsinki II changed the terminology of Helsinki I to "Clinical
Research" and "Non-Clinical Biomedical Research., 77 In addition, it
emphasized the informed consent requirement by placing it among the
78
twelve basic principles and expanding it to include three principles.
Furthermore, Helsinki II, for the first time, created a deterrent (though
minimal) to the exploitation of human subjects; those experiments not in
compliance with the principles will not be accepted for publication.79
Moreover, in terms of the current issue, Helsinki II requires research
on human subjects to conform to "generally accepted scientific
principles." 80 Unfortunately, it does not specify whose scientific
principles are to be considered acceptable - the principles of the
71.

The Committee on Medical Ethics was selected to "grapple" with the issue. Id.

72.

While the Code served as a guide, it was never mentioned in Helsinki I or any

successive drafts of the Declaration of Helsinki.
73. See generally, DECLARATION OF HELSINKI: RECOMMENDATIONS GUIDING
MEDICAL DOCTORS IN CLINICAL RESEARCH, reprintedin THE NAZI DOCTORS, supra note

57, at 331 [hereinafter DECLARATION OF HELSINKI I-IV].
74. InternationalOverview, supra note 66, at 158.

75. Id. at 159.
76. Id.
77.

DECLARATION OF HELSINKI I-IV, supra note 73, HELSINKI II, Principle II, III.

78. Id., Principle 1.9-11.
79. Id., Principle 1.8.
80. Id., Principle 1.1.
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sponsoring or the host nation. In addition, Helsinki II requires every
patient to be assured of, and any new treatment to be weighed against,
the "best current diagnostic and therapeutic methods.",8 1 This provision
of the international document also does not provide further guidance
regarding whether the "best current diagnostic and therapeutic methods"
are to be defined in terms of the sponsoring or the host country.
While the Code and the Declaration of Helsinki provide the basis
for universality of ethical standards in human experimentation, neither
holds legally binding authority.82 Therefore, binding ethical standards in
the form of national or international regulations were still needed.83
3.

International Guidelines for Biomedical Research Involving
Human Subjects.
In 1982, the Council for International Organizations of Medical
Sciences (CIOMS), with the assistance of the World Health Organization
(WHO), issued one of the most significant developments in the
international realm of medical research ethics: "Proposed International
Guidelines for Biomedical Research Involving Human Subjects" (the
"Guidelines").84 The Guidelines are based on Helsinki II and serve as a
guide to countries promulgating their own regulations regarding ethical
conduct in research involving human subjects.85
The Guidelines provide the first source of standards for
international research conducted by developed countries in developing
countries. In particular, it requires research to be completed by subjects
in developed countries, unless certain circumstances necessitate
elsewhere. 86 Intended to protect human subjects' rights, the Guidelines
identify vulnerable groups who may be incapable of protecting their own
81. Id., Principle 11.2, 11.3.
82. International Overview, supra note 66, at 160. One commentator noted "'the
various declarations and codes defining ethical aspects of research on human subjects
[are] really no more than pious hopes that doctors [will] behave ethically."' Id. (quoting
ALFRED GELLHORN, Medical Ethics in the Modern World, in MEDICAL EXPERIMENTATION
AND THE PROTECTION OF HUMAN RIGHTS, at 9 (Norman Howard-Jones & Zbigniew

Bankowski, eds., Geneva: Council for International Organizations of Medical Sciences
and Sandoz Institute for Health and Socio-Economic Studies, 1979)).
83. See InternationalOverview, supra note 66, at 160.
84. Id.The authors note that the word "proposed" does not mean that the guidelines
have not been promulgated, rather the guidelines are proposed to countries as national
standards of ethical conduct. Id. at 160-61.
85. See id. at 162. The guidelines are meant to provide a "framework upon which
countries that have not yet formalized their regulatory requirements for the ethical review
of research protocols may build." Id.
86. PROPOSED INTERNATIONAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS, reprinted in ETHICS AND RESEARCH ON HUMAN BEINGS:
INTERNATIONAL GUIDELINES (Z. Bankowski & R.J. Levine eds., 1993), Guideline 8
[hereinafter PROPOSED INTERNATIONAL GUIDELINES].
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interests due to a host of impediments. The Guidelines identify duties
that an investigator must follow before obtaining informed consent.
Specifically, an investigator has the obligation to give potential subjects
pertinent information to aid in their decision to participate in the research
and to exclude all possibilities of coercion or undue influence.88
Concerned that investigators in developed countries may serve selfinterests rather than the interests of the human subjects in the developing
countries, the Guidelines mandate the ethical review of all experiments
by both the sponsoring and the host country. 89 Based on these new
ethical guidelines, the emphasis is no longer on the informed consent of
the subject, but rather on the ethical review of the experimental
procedure itself.90 Hence, the Guidelines diverge from the two previous
international standards, yet still capture the essence of the underlying
principle - protection of a research subject's rights and well-being. 9'
The most significant distinction from the other international codes,
as viewed in terms of this comment, is the Guidelines' implication that
the ethical standards applied by the ethical review committee be "no less
exacting than they would be in the case of research carried out in [the
sponsoring] country. 92 Therefore, while the Guidelines do not provide
the legal authority on ethical standards that they were hoped to have
provided, they offer critics of the trials conducted in the Ivory Coast an
origin for their argument that regulations of the United States should
govern the research it conducts in developing nations.
B.

United States Regulations

1. The Belmont Report
In 1979, the United States National Commission for the Protection
of Human Subjects of Biomedical and Behavioral Research (the
"Commission") promulgated the Belmont Report: a statement of basic
ethical principles and guidelines signed into law to assist scientists,
subjects, reviewers, and interested citizens in resolving ethical issues

87. PROPOSED INTERNATIONAL GUIDELINES, supra note 86, Guideline 10.
88. Id., Guideline 3.
89. Id., Guideline 15.
90. See International Overview, supra note 66, at 163. "By mandating ethical
review, the Guidelines provide for exceptions to the absolute requirement of informed
consent in instances where consent may not be obtainable, yet experimentation on human
subjects may still be ethically and morally justified." Id.
91. Id. at 165. "Even though the emphasis has shifted from informed consent to
ethical review, the underlying principles, established to protect the rights and welfare of
the research subject, remain basically the same." Id.at 164.
92. PROPOSED INTERNATIONAL GUIDELINES, supra note 86, Guideline 15.
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stemming from human experimentation. 93
The Belmont Report identifies three basic ethical principles:
autonomy, beneficence, and justice.9 4 Autonomy requires respect for
persons and protection for those with a diminished capability of selfdetermination.9 5 Respect for those participating as human subjects
demands that they are adequately informed before they voluntarily
consent to the research.9 6
Beneficence is an extension of the Hippocratic maxim "do no
harm., 97 The Commission defined beneficence as an obligation to (1) do
no harm and (2) maximize possible benefits while minimizing possible
harms.9 8 Investigators are obligated to maximize the benefits of the
research and reduce the risk to subjects that may arise during the
experiment. 99
Finally, justice requires that everyone be treated equally. In the
human research realm, justice demands that the selection of subjects be
random, rather than systematically selected on the basis of their
manipulability or compromised situation.10 0 In addition, justice requires
that the advantages of the0 studies benefit all that participate, not just
those that can afford them.' 1
2.

Department of Health and Human Services and the Food and
Drug Administration.
In 1990, both the Department of Health and Human Services
(DHHS) and the Food and Drug Administration (FDA) passed federal
legislation, which provided additional guidance for the protection of
human research subjects. 0 2 These regulations delineate a heightened
importance on obtaining informed consent from every participant before
research is conducted.
Essentially, the two pieces of legislation are identical; both identify
eight basic requirements for informed consent, along with additional
elements that may be appropriate in certain situations such as when
research is conducted on embryos or fetuses. 10 3
The general
requirements identify the specific information that must be given to the
93. THE BELMONT REPORT, 44 Fed. Reg. 23192, 23192-93 (April 18, 1979).
94. Id. at 23193-94.
95. id. at23193.
96. Id.at23194.
97. Id.
98. Id.
99. THE BELMONT REPORT, supra note 93, at 23194.
100. Id.
101. See id.
102. DHHS Protection of Human Subjects, 45 C.F.R. §46.116 (1990) and FDA
Protection of Human Subjects, 21 C.F.R §50.25 (1990).
103. Id.
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potential subjects prior to the start of the research including an
explanation of the purpose(s) of the research, a description of
10 4 all
participants.
the
to
benefits
any
of
disclosure
a
and
risks
foreseeable
In addition, the regulations require the research subject(s) to be
given the opportunity to decline participation prior to the investigator
Of utmost importance, the
obtaining the subject's consent. 10 5
is not subject to coercion or
that
the
participant
investigator must ensure
information in a language
undue influence and must provide all10 pertinent
6
that is understandable to the subject.
V.

National Bioethics Advisory Commission 2001 Recommendations

Due to the increasing number of developed countries conducting
research on subjects in developing countries, with specific attention on
the AZT trials in the Ivory Coast, questions regarding the ethics of these
studies emerged. 0 7 In particular, there was a growing concern that the
research was, or had the potential for, exploiting both the host country
and those who participated in the research studies.'0° Once again, readily
identifiable research standards were desired in order to ensure the safety
of those involved in human experimentation.' 0 9
0
On October 3, 1995, President Clinton signed an executive order"
creating the National Bioethics Advisory Commission (NBAC)."' The
NBAC's essential functions included providing guidance to the National
Science and Technology Council and other government entities on
matters regarding government regulations addressing "bioethical issues
arising from research on human biology and behavior."' "12 In addition,
the NBAC was required to identify broad principles that would govern
the ethical conduct of human research. 1 3 More specifically, the NBAC
104. Id.
105. Id.
106. Id.
107. See EXECUTIVE SUMMARY, supranote 1,at i.
108. Id.
109. Many issues were contributing to the need for a comprehensive study on ethical
standards of human research. Among other issues, scientists in developing countries are
achieving equitable status as researchers and there is a growing concern that United
States regulations were simply "bundled" and "exported" to other countries, forcing the
host country to interpret them. I NBAC ETHICAL AND POLICY ISSUES IN INTERNATIONAL
CLINICAL
RESEARCH:
RECOMMENDATIONS, at 3

TRIALS

IN

DEVELOPING

COUNTRIES:

REPORT

AND

(2001) [hereinafter REPORT AND RECOMMENDATIONS] available
at http://www.georgetown.edu/research/nrcbl/nbac/pubs.html.
110. Exec. Order No. 12975.
111. The NBAC consisted of Harold T. Shapiro, Ph.D., serving as the NBAC chair,
and seventeen other members. In addition, an extensive research staff and other
consultants contributed to this expansive study of bioethics.
112. EXECUTIVE SUMMARY, supra note 1, inside front cover.
113. Id.
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was to investigate whether the existing rules and regulations' governing
the United States' expanding realm of human research, remain the
appropriate standards when such research is conducted outside the
14
United States.'
In April 2001, the NBAC published its final report, 1 5 proposing
twenty-eight recommendations that addressed the ethical issues that arise
when research, which is subject to United States regulation, is sponsored
or conducted in developing countries. These recommendations stress the
need for sponsoring countries to assist the host countries in becoming
capable of self-regulating human research conducted within its
boundaries.' 16
However, until this need is met, the NBAC's
recommendations will serve as a basis for how the "United States should
proceed in settings in which systems for protecting human participants7
equivalent to those of the United States have not yet been established."",1
Essentially, the NBAC's recommendations serve as the substantive
ethical requirements for protecting those involved in human
experimentation.
Of primary concern is the NBAC's perspective
regarding its recommendations: "Although the ethical standards that this
report is recommending for conducting research in other countries are
minimum standards, host countries are encouraged to adopt human
research participant protections that go beyond those that are currently
provided under the United States system."' 1 8 This comment will only
focus on those "minimum" recommendations that specifically address
three paramount ethical issues: informed consent, placebo versus best
available treatment and availability of treatment after the research trials.
The NBAC stressed that all international research conducted on
humans should conform, at a minimum, to the ethical principles
delineated in the Belmont Report.1 9 Therefore, its first recommendation
states:
Recommendation 1.1: The U.S. government should not sponsor or
conduct clinical trials that do not, at a minimum, provide the
following ethical protections:
a) prior review of research by an ethics review
committee(s);
114. See id. at i.
115. This report represents the fifth NBAC report, submitted to President Clinton. It
is the culmination of eighteen months of study, focusing on both domestic and
international standards of bioethics. Letter from Harold T. Shapiro, Chair, National
Bioethics Advisory Commission, to President Clinton (April 18, 2001), reprinted in
REPORT AND RECOMMENDATIONS, supra note 109, at 1.
116.

EXECUTIVE SUMMARY, supra note 1, at ii.

117. Id.
118. REPORT AND
119. See id. at 5.

RECOMMENDATIONS, supra note 109, at

6.
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b) minimization of risk to research participants;
c) risks of harm that are reasonable in relation to potential
benefits;
d) adequate care of and compensation to participants for
injuries directly sustained during research;
e) individual informed consent from all competent adult
participants in research;
f) equal regard for all participants; and
g) equitable distribution of the burdens and benefits of
research. 120
While this preliminary recommendation serves as an overview,
subsequent recommendations delineate how to specifically meet the
NBAC's "minimum standards."
For example, obtaining voluntary
informed consent from every research subject has proven difficult,
especially in developing countries, where a plethora of communication
barriers exist. Therefore, the NBAC provided further guidance on
overcoming obstacles when obtaining informed consent.
A.

Informed Consent

Obtaining voluntary informed consent has been a fundamental
principle of research ethics, as evident in the Declaration of Helsinki, the
Belmont Report and both the DHHS and the FDA requirements.121 Its
necessity stems from the simple fact that "the use of human beings as a
means to the ends of others without their knowledge and freely
granted
' 22
permission constitutes exploitation and is therefore unethical.'
For the purposes of its report, the NBAC adopted as the definition
of informed consent: "the process by which an individual voluntarily
expresses his or her willingness to participate in a particular trial, after
having been informed of all aspects of the trial that are relevant to the
decision to participate."' l2 3 The NBAC, elevating substance over form,
stressed the process of obtaining the consent rather than the document
120. Id., Recommendation 1.1, at 6.
121. The requirement of informed consent is "reflected in all published national and
international codes, regulations, and guidelines pertaining to research ethics, including
those in many developing countries." REPORT AND RECOMMENDATIONS, supra note 109,
at 35.
122. See id at 36.
123. Id. at 37. The NBAC adopted this definition from the International Conference
on Harmonisation (ICH) GUIDELINE FOR GOOD CLINICAL PRACTICE, GCP Guideline 1.28
(ICH 1996). REPORT AND RECOMMENDATIONS, supra note 109, at 37. Utilizing this
definition, the NBAC recommended: "Research should not deviate from the substantive
ethical standard of voluntary informed consent. Researchers should not propose,
sponsors should not support, and ethics review committees should not approve research
that deviates from this substantive ethical standard." 1d, Recommendation 3.1, at 38.
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that contains the written consent of the participant. 124 Finally, the NBAC
125
made further recommendations to ensure the consent process is ethical.
1.

Cultural Issues Related to Presenting Information to
Participants
The NBAC considered four types of disclosure fundamental to
achieving voluntary informed consent: disclosure of diagnosis and risk,
disclosure of the use of placebos and randomization, disclosure 1 of
26
alternative treatments and disclosure about possible post-trial benefits.
These four disclosures are important because cultural differences arise
within each and in order to ensure every subject completely understands
the research to be conducted, investigators must first be aware of the
difficulties they may face in other countries.1 27 In its report, the NBAC
stressed that these cultural differences shall
not be overlooked when
28
obtaining consent from research subjects.
Another obvious cultural barrier is language. Participants may not
fully understand the technical and scientific jargon underlying the
studies.129 Countries with low literacy rates, including the Ivory Coast,
may not even understand a written consent form.' 30 Furthermore, in
some countries, certain individuals are unable
to decide for themselves
3
whether they may participate in the protocol. 1 '
To address these additional cultural barriers, the NBAC proposed
the following recommendations:
Recommendation 3.4:

Researchers should develop procedures to

124. Id. at 37.
125. The NBAC identified the ideal consent process: the sponsoring team provides
information to the subject and ensures that the subject voluntarily agrees to the research
study only after the team makes a determination that the subject understands the
information provided to him or her. REPORT AND RECOMMENDATIONS, supra note 109, at
37.
126. "Researchers should develop culturally appropriate ways to disclose information
that is necessary for adherence to the substantive ethical standard of informed consent,
with particular attention to disclosures relating to diagnosis and risk, research design, and
possible post-trial benefits. Researchers should describe in their protocols and justify to
the ethics review committee(s) the procedures they plan to use for disclosing such
information to participants." Id, Recommendation 3.2, at 40.
127. For example, in some countries, it is customary for physicians to routinely
withhold certain information from their patients, whether in a clinical or research setting.
See REPORT AND RECOMMENDATIONS, supra note 109, at 38-39.

128. Id. at 39-40.
129. Id. at 40.
130. Seeidat4l.
131. Instead, a community leader or a woman's spouse or father must first give
permission for the individual to become a research subject. Moreover, researchers may
have to seek a community leader's consent before even approaching potential
participants. Id. at 42-44.
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ensure that potential participants do, in fact, understand the
information provided in the consent process and should describe
those procedures in their research protocols.
Recommendation 3.5: Researchers should consult with community
representatives to develop innovative and effective means to
communicate all necessary information in a manner that is
understandable to potential participants.
When community
representatives will not be involved, the protocol presented to the
ethics review committee
should justify why such involvement is not
13 2
possible or relevant.
Despite the apparent "ethical centrality" of informed consent in
research regulations, problems exist not only because of cultural
differences resulting in ineffective communication, but also because the
standard is, in fact, not universally embraced.133 Nonetheless, the NBAC
felt confident that United States investigators, even faced with cultural
diversity, would be able to obtain voluntary informed consent.134 In fact,
while the NBAC has repeatedly admitted the difficulties in implementing
sound procedures to overcome cultural barriers, 3 1 it still maintains that
36

voluntary informed consent can be obtained.1
Considering the various cultural barriers, it is simply not feasible
that every participant will fully understand research procedures in order
to voluntarily consent to the study. In fact, it is not too harsh a statement
that there should be a presumption that consent cannot be adequately
obtained when international
research is conducted by a foreign nation in
137
a developing country.

The NBAC recommended that "[r]esearchers should develop
culturally appropriate ways to disclose information, ' 138 and gave
substantive examples researchers can use to ensure adequate disclosure
and understanding. 39 While the NBAC identified the potential areas in
which cultural differences will be most prevalent, it nonetheless still
132. REPORT AND RECOMMENDATIONS, supra note 109, Recommendation 3.4, 3.5, at
42.
133. See id at 35. One commentator states that it "is 'ethical imperialism' at its worst
to assume that the informed consent requirement.., is in itself such a universal ethical
standard." Id.at 36.
134. See id. at 36.
135. "Although the Commission recognizes the challenges raised by these cultural
differences...
Despite the acknowledged difficulties of administering tests of
understanding..." Id.at 40-42.
136. See id.
at 50.
137. See Maternal-FetalHIV Transmission,supra note 47.
138. See REPORT AND RECOMMENDATIONS, supra note 109, Recommendation 3.2, at
40.
139.

See REPORT AND RECOMMENDATIONS, supra note 109, at 41.
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leaves the method of disclosure to the investigators themselves.
In fact, the NBAC claimed that if researchers are "willing to devote
the time and effort to do so, [they] often are able to devise creative
measures for overcoming the cultural barriers."'1 40 Hence, discretion in
the methodology and the amount of information given to research
subjects remains with the investigators. As seen thus far, regulations that
provide no clear-cut guidelines have resulted in exploitation or the
potential exploitation of human beings in developing countries because
researchers are not willing to make the time or effort to ensure clear
communication with their subjects.
2.
Issues Relating to Voluntary Participation in Research
The NBAC denoted that the fundamental principle of informed
consent requires that consent be voluntary. 14 1 However, ensuring that a
subject remains free of coercion and undue influence is among the most
difficult requirements. 142 It is unlikely that a research subject would
willingly participate in a research study if it was void of any benefits to
the community or to him or herself.143 If participants are offered medical
treatment, to which they would not normally have access, however, they
may consent to the research to obtain the medicine. Thus, while the
research subject's consent has been voluntarily obtained, it was only
obtained because the subject wished to receive free medication. Hence,
individuals, such as the pregnant women taking the AZT drug, may be
unduly influenced 144
to participate in research studies that provide even
minimal treatment.

When asked if it believed that the AZT studies were ethical, the
CDC not only stated that the studies were consistent with both the United
States and international ethical standards but it also outlined the vast
amount of information that was given to the participants. 145
140. Id. For example, investigators can analogize the research study to a familiar
process in the host country. NBAC also suggests the use of intermediaries and the
translation and back translation of a written consent form to ensure understanding. Id.
141. Id. at 45. "Researchers should strive to ensure that individuals agree to
participate in research without coercion or undue inducements from community leaders
or representative." Id., Recommendation 3.7 at 44.
142. See id.
143. See Maternal-FetalHIV Transmission, supra note 47. A poor African woman is
unlikely to participate if only the pharmaceutical company and its developed country
would benefit. Id.
144. "This situation is likely to exist in developing countries in which large numbers
of people have little or no access to medical care and treatment even for ordinary
illnesses." REPORT AND RECOMMENDATIONS, supra note 109, at 46.
145. "Women are clearly told that the AZT regimen might or might not be effective.
Women are clearly told about possible risks of AZT. Women were clearly told that some
would receive AZT and others would not. Women are clearly told that they would be put
into one group or the other by chance and that neither they nor their doctors would know
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Nevertheless, the participants in the studies were not adequately
informed and merely consented because of the medicine they would
receive.
One AZT participant reported that she did "not quite grasp - even
after repeated questioning" what drug she was taking and for what
purpose. 146 Moreover, she, along with most of the other participants,
admitted that she consented to the research because it provided her and
her baby free medical care that she otherwise would have been unable to
receive.1 47 Most participants agreed that the prospect of help during and
after their pregnancy "made taking part in the experiment all but
irresistible." 148 Some women only received a five minute briefing,
during which most of the women, even the most highly educated ones,
never fully understood the research; the subjects felt they had no other
149
choice if they wanted to save their children.
Despite such inducement, the NBAC concluded that it was not
enough to curb a subject's voluntary decision to participate in the
research. 150 This is a bold conclusion, considering that both the NBAC
and commentators deem informed consent a cornerstone of research
ethics and agree that the quality of informed consent can be
compromised based on the participant's beliefs. 151 The NBAC has
admitted that its recommendations are only the first step in obtaining
voluntary informed consent; 152 however, in order to adequately protect
participants, clearer standards are necessary.
B.

Placebo v. Best Available Treatment

Despite the clear mandate in Helsinki II that research on human
subjects must conform to "generally accepted scientific principles" and
which group they were in." Questions and Answers, supra note 10.
146.

Howard W. French, AIDS Research in Africa: Juggling Risks and Hopes, N.Y.

1997, at Al. Interviews with other women revealed that they did not
understand the complexity of the ethical and scientific issues stemming from the research
study. Id.
147. Id.
148. Id.
149. Id. Even the American investigators conducting the study were not told all the
pertinent details. One researcher reported that he was never told that the same study
could not be conducted in the United States. Instead, he was only told that the study was
consistent with "the strictest American and international standards for medical research."
Moreover, the investigators were told not to speak about their work. Id.
150. REPORT AND RECOMMENDATIONS, supra note 109, at 47.
TIMES, Oct. 9,

151. Ruth Faden & Nancy Kass, HIV Research, Ethics, and the Developing World, 88
AM. J. PUB. HEALTH 548 (1998). ("All too often, a research project offers the best

medical care or the only medical care available, and it may be impossible for potential
subjects who are ill or at risk to refuse research participation.")
152. REPORT AND RECOMMENDATIONS, supra note 109, at 51.
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more specifically, that any new treatment is to be weighed against the
"best current diagnostic and therapeutic methods,"' 153 the AZT trials did
not meet this standard. Nor did the trials meet the Guidelines' ethical
standard that the treatment be "no less exacting than they would be for
research carried out within the initiating country."' 154 Instead a shorter
and less effective AZT treatment was given and was only compared to a
placebo rather than the full treatment that had been utilized in the United
States research trials.
In its report, the NBAC focused on the crucial question of whether a
research study that could not ethically be conducted in the sponsoring
country, typically a developed country, could ethically be conducted in a
developing country.155 To address this inconsistency, the NBAC
proposed the following recommendation:
Recommendation 2.2: Researchers and sponsors should design
clinical trials that provide members of any control group with an
established effective treatment, whether or not such treatment is
available in the host country. Any study that would not provide the
control group with an established effective treatment
should include a
156
justification for using an alternative design.
This recommendation is contrary to Helsinki's "best current
method" and is obviously in conflict with the Guidelines' requirement
that the host country receive the same treatment as the sponsoring
country. 157 The NBAC argued that requiring the same treatment leads to
"the patently absurd conclusion that a country would somehow be
applying a different ethical standard if its rules for prior independent
review of research stipulated, for example, a different composition of
research ethics committees than that required for United States
research."'1 58 In other words, the NBAC is concerned that a host country
might have more stringent ethical standards than the sponsoring country
and, thus, be forced to adhere to substandard requirements. This
argument, however, lacks foundation especially when applied to the AZT
trials; the developing country has no ethical standards in place, let alone
more stringent standards.
153. See supra text accompanying note 81.
154. See supra text accompanying note 92.
155. REPORT AND RECOMMENDATIONS, supra note 109, at 8. It may be unethical for
researchers to go abroad and implement studies that would not be permitted in their own
countries. "The exportation of research risks, and importation of valuable scientific
knowledge, appear not only inequitable, but repetition of the research practices that were
strongly condemned at Nuremberg." Dickens, supra note 2, at 195.
156. REPORT AND RECOMMENDATIONS, supra note 109, Recommendation 2.2, at 28.
157. See supra text accompanying note 89.
158. Id.at 9.
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The NBAC also argued that its ethical standard is better than the
"best current method" standard because there is discrepancy in the
medical field as to what treatment is the best.1 59 Yet, the NBAC
conceded that "it can be difficult to determine whether an intervention
constitutes an established effective treatment." 160 Thus, its argument
against using the stricter standard in Helsinki II adversely applies to its
own recommended standard.
Nonetheless, the NBAC has maintained that its "established
effective treatment" standard is "reasonably clear" and "best conveys
what is owed to research participants during a study,"1 6' yet agreed that
"it would not be ethical to give participants a placebo [if] doing so would
pose undue risk to their health or well-being.'' 162 Hence, while the
NBAC's new ethical standard of treatment is not as strict as current
international standards, it may have prevented the death of approximately
1,000 children during the AZT trials 163 by administering a treatment
more effective than a simple placebo.
C.

Availability of Treatment after the Research Trials

The NBAC also addressed another critical question in its report:
What amount of treatment, if any should be made available to the
64
research subjects and to others in the host country following the study?'
The majority of women in developing countries cannot afford the shorter
dose of AZT, yet alone the full dosage;165 therefore, how can a less
effective, low-cost intervention be beneficial to a host country where no
one has access to it following the completion of the trial?
Spokesmen from both the NIH and the CDC justify the AZT studies
because the results provided information that the host country can use to
determine how to make the intervention available after the trials are
concluded. 66 However, this suggestion leads the host country to
determine what to do with research results that it did not even conduct.
Commentators are outraged at this suggestion: "[W]hat these countries
require is not good intentions, but a real plan to deliver the
159. Id. at 10. ("NBAC recognizes that there are often many effective treatments for
a given condition and that some controversy exists over which may be considered
'best.')
160. Id. For example, one population, due to different medical or social resources and
conditions, demographics or other characteristics, may react differently to an intervention
than another population, thus making it more or less effective. Id.
161. Id.
162. EXECUTIVE SUMMARY, supra note 1, at iv.
163. See supra text accompanying note 30.
164. REPORT AND RECOMMENDATIONS, supra note 109, at 12.
165. See supra text accompanying note 44.
166. Maternal-FetalHIV Transmission,supra note 47.
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intervention."1
In response to this dilemma, the NBAC proposed the following
recommendation, as pertinent:
Recommendation 4.1: Researchers and sponsors in clinical trials
should make reasonable, good faith efforts before the initiation of a
trial to secure, at its conclusion, continued access for all participants
interventions that have been proven effective
to needed experimental
1 68
for the participants.
While this recommendation suggests the importance of providing
the participants access to the treatment, it does not guarantee delivery of
the intervention. The NBAC should mandate that the drug intervention
be made available, not leave yet another aspect of the research trials to
the discretion of the investigators. 169 Unless the treatment is made
available to the host country, and more importantly, to the research
participants, "developed countries are simply exploiting them in order to
from the clinical trials for the
quickly use the knowledge gained
170
developed countries' own benefit."
The NBAC proposed Recommendation 4.1 because the issue of
treatment made available after trial completion remained unaddressed by
United States guidelines,1 71 yet the NBAC does not adequately solve the
issue with its own proposal. Investigators are still left with the discretion
to determine what are "reasonable" efforts to ensure treatment, and
whether it is made available. In addition, the investigators only have to
make a "good faith" effort to implement the intervention(s). The
question remains: Who determines whether the sponsor is putting forth a
"good effort"? Who is enforcing these regulations?
Some developing countries have bypassed United States and other
167. Id. It is a relatively common occurrence that even inexpensive and effective
treatments are not distributed to those in developing countries, particularly Africa. For
example, an inexpensive and effective treatment to reduce the transmission of sexually
transmitted diseases was never delivered to rural Tanzania. Id.
168. REPORT AND RECOMMENDATIONS, supra note 109, Recommendation 4.1, at 74.
169. One researcher from a developing country commented, "'[i]t should be made a
requirement that [if developing country] research involving testing of drugs and other
interventions [is] found efficacious, the participating populations should be among the
first ones to benefit, at affordable costs."' REPORT AND RECOMMENDATIONS, supra note
109, at 56 (quoting Nancy Kass & Adnan A. Hyder, Attitudes and Experiences of U.S.
And Developing CountryInvestigatorsRegarding U.S. Human Subjects Regulations, in II
NBAC, ETHICAL AND POLICY ISSUES IN INTERNATIONAL RESEARCH: CLINICAL TRIALS IN
DEVELOPING COUNTRIES: COMMISSIONED PAPERS AND STAFF ANALYSIS B-I, B-98 (2001))
availableat http://www.georgetown.edu/research/nrcbl/nbac/pubs.html.
170. Maternal-FetalHIV Transmission, supra note 47.
171. REPORT AND RECOMMENDATIONS, supra note 109, at 55. Thus far, regulations
have simply advised that the issue of access is to be discussed prior to the inception of the
study. Id. at 57.
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developed countries by taking the extra step and imposing affirmative
obligations on the investigators to provide any172effective treatment to the
participants, as well as the general population.
Unfortunately, once again, the United States has no clear
enforcement mechanisms for its research guidelines.
In the past,
173
bioethical guidelines failed to provide a source of binding authority,
which resulted in less than acceptable research trials, leaving participants
without a remedy. While the NBAC's recommendations address the
growing number of crucial ethical issues in international human research,
they do not possess the binding authority the world needs to provide
adequate protection of the rights and welfare of human beings, primarily
in developing countries.
VI. Will Exploitation Continue?
Human research will continue to be an important source of
statistical data as incurable diseases and new strains of illnesses entice
aggressive companies and governmental agencies to find a cure or a lifesaving drug, likely all with human beings acting as guinea pigs.
Those wishing to reach the finish line first may take shortcuts, try to
evade national and international regulations and unknowingly or even
intentionally compromise a subject's rights along the way. In the past,
such violations have raised eyebrows and even spurred the promulgation
of legislation to ensure the safety of the human race. Yet, the world has
failed to establish enforceable bioethical guidelines that will ensure the
protection of human subjects.
Faced with a difficult and narrow task, the NBAC proposed twentyeight recommendations, addressing potential ethical issues that may arise
prior to, during, or even after a human experiment. 174 In particular, the
NBAC focused on ensuring voluntary informed consent is obtained from
every participant, effective treatment is administered during the
intervention and access to the treatment is given following the
completion of the research.
While the NBAC has made great strides to protect human subjects
and is commended for its efforts, the recommendations proposed simply
fail to provide the binding authority needed to overcome unethical
behavior. The potential to exploit human beings, especially those living
in developing countries, remains. Investigators are still given discretion
in determining themethodology and the amount of information given to
research subjects; United States administrative agencies, despite clear
172.
173.

Uganda and Brazil are among the nations to adopt such a requirement. Id.
See supra text accompanying notes 82, 83.

174.

See supra Section V.
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cries from research participants, still maintain that subjects are informed
and voluntarily consented to the research; subjects will be given an
"established effective treatment" rather than the best available treatment;
"good faith" efforts will not meet the demand for inexpensive yet proven
treatment; and "minimum standards" will not save the next generation of
babies born to HIV infected women in Africa.

